Physician profile
Myrna E Alexander
NPI 1285648063
$4,618.32
in general payments reported to CMS, 2019-2025
25 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,577 · 2020: $329 · 2021: $608 · 2022: $957 · 2023: $848 · 2024: $127 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $840.22 | 2019-2024 | |
| Abiomed | $496.26 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $441.42 | 2019-2023 | |
| Amgen INC. | $374.15 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.81 | 2019-2023 | Jardiance |
| Cvrx, INC. | $260.62 | 2023-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $211.19 | 2019-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $201.94 | 2019-2023 | Brilinta |
| Boston Scientific Corporation | $151.46 | 2022 | |
| Janssen Pharmaceuticals, INC | $149.63 | 2019-2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $142.73 | 2019 | |
| Irhythm Technologies, INC. | $131.58 | 2019 | |
| Amarin Pharma, INC. | $121.85 | 2019 | |
| Impulse Dynamics (USA) INC. | $103.61 | 2022-2023 | Optimizer |
| Astellas Pharma US INC | $100.94 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $97.13 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $82.68 | 2022-2023 | Uptravi |
| Gilead Sciences, INC. | $77.28 | 2019 | |
| Akcea Therapeutics, INC. | $71.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $68.01 | 2022 | |
| Abbott Laboratories | $65.16 | 2021-2025 | Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $54.31 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $24.28 | 2019 | |
| Ge Healthcare | $23.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myrna Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.